Tags

  • Sorting

  • Filters

How to Detect Additives in Cosmetics Amongst Ever Changing Regulations

In today’s technical blog, I’m talking about the cosmetics industry so let’s get right to it. According to a Research and Market report, “The Global Cosmetic market was $460 billion USD in 2014 and is estimated to reach 675 billion USD by 2020, growing at a rate of 6.4%.”1 The U.S. leads the pack with a reported $62 billion in revenue earned in 20162. So, what am I getting at? We know earnings are strong and consumers like their products. But the question remains, are these products that you put on your skin, hair, and ingest safe? Such is the thinking of scientists like me and other chemists who are routinely tasked with detecting minimal levels of potentially harmful ingredients in personal care products against ever-changing global regulations.

A Mine of Quantitative Proteomic Information

The Aebersold group at ETH Zurich focuses on proteomics research, including the development of techniques to study the proteome as an integrated entity. In collaboration with SCIEX, the group established SWATH® Acquisition mass spectrometry, a data-independent acquisition (DIA) method capable of fragmenting multiple peptide species concurrently. The resulting comprehensive data set can be retrospectively re-mined, enabling maximum benefit to be derived from any study.

Delivering New Biologics to the Marketplace

Characterization and quantification of host cell proteins (HCPs) in biopharmaceutical development and manufacturing is a critical step to ensuring product safety. While this can be achieved using ELISA, mass spectrometry using the SCIEX TripleTOF® 6600 System is more specific and enables the identification and quantitation of each of the individual proteins present.

Speeding the Development of Quantitative Biosimilar Assays

When developing new quantitative assays for Biotherapeutics, every biologic requires a specific sample prep strategy, which includes sourcing reagents and research protocols. However, as every bioanalytical lab knows all too well, it can also take up to two months to develop an optimized and robust LC-MS assay. For this reason, researchers understandably want an easier way to develop highly sensitive and specific assays for biotherapeutics and biosimilars to accelerate sample turnaround time.

Detecting low levels of drugs and their metabolites in hair and nail samples using LC-MS/MS

Detecting low levels of drugs and their metabolites in hair and nail samples using LC-MS/MS

You probably have heard of testing blood and urine samples for the presence of drugs and their metabolites. But do you know about the benefits of hair and nail analysis? In a recent webinar, Tina Binz, Deputy Head of the Center for Forensic Hair Analysis, University of Zurich, discussed the benefits of developing comprehensive and sensitive LC-MS/MS for the detection of low-level drugs and metabolites in keratinized matrices.

Guide decisions during cell line development with more information at the intact level

Guide decisions during cell line development with more information at the intact level

Monitoring product quality attributes (PQAs) throughout monoclonal antibody (mAb) development is vital to ensuring drug safety and efficacy. By adopting orthogonal analytical techniques and integrating new technologies that have the potential to provide more information, it is possible to improve product quality and manufacturing efficiency and make more informed decisions.

Maximize NPS analysis with accurate mass spectrometry

Maximize NPS analysis with accurate mass spectrometry

LC-MS/MS is a powerful analytical tool in forensic toxicology testing that can support a variety of testing regimes such as screening, confirmation and quantitative workflows. More specifically, analysis of NPS using LC-MS/MS provides many advantages, including the ability to reliably detect new drugs and their metabolites from a variety of biological matrices.

What has the Echo® MS system done for the pharma industry? (And don’t just take our word for it!)

What has the Echo® MS system done for the pharma industry? (And don’t just take our word for it!)

SCIEX was very proud to have an illustration of the Acoustic Ejection Mass Spectrometry (AEMS) technology that powers the Echo® MS system on the front cover of the Journal of the American Society for Mass Spectrometry in January 2023. The associated article—Ultrahigh-Throughput Intact Protein Analysis with Acoustic Ejection Mass Spectrometry—was co-authored by scientists from SCIEX and Merck.

Rescheduling a Schedule I substance, and the Delta-8 controversy

Rescheduling a Schedule I substance, and the Delta-8 controversy

Did you know that in the US, drugs and other chemicals are classified into 5 distinct categories depending on the drug’s acceptable medical use and its potential for abuse or dependency?  Drugs federally classified as Schedule I substances by the US Drug Enforcement Administration (DEA) are considered to have the highest potential for abuse and for creating severe psychological and/or physical dependence. In addition to heroin, LSD and MDMA (ecstasy), cannabis is classified as a Schedule I substance in the Controlled Substance Act of 1970, which means it has no approved medical usage.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Wordpress Social Share Plugin powered by Ultimatelysocial